Document is current
Any future updates will be listed below
-
Authors
Shortt, Gabrielle
Shortt, Nicholas
Bird, Georgina
Kerse, Kyley
Lieffering, Nico
Martin, Alexander
Eathorne, Allie
Black, Bianca
Kim, Bob
Rademaker, Marius
Reiche, Louise
Paa, Selwyn Te
Harding, Suki
Armour, Mike
Semprini, Alex
-
Funding
Funding for this research was provided by:
Callaghan Innovation (MBIOS2003)
- License Information
-
More Information
Article History
Received: 6 March 2023
Accepted: 14 January 2024
First Online: 29 January 2024
Declarations
:
: This study has been approved by Central Health and Disability Ethics Committee (HDEC reference: 2021 EXP 11490). National Standing Committee on Therapeutic Trials (SCOTT) approval has been obtained (21/SCOTT/118), as required for all clinical trials investigating a new medicine under Aotearoa New Zealand legislation [CitationRef removed]. Written informed consent to participate will be obtained from all participants. All methods have been performed in accordance to guidelines and regulations set forth by HDEC and SCOTT.
: Not applicable.
: SH is the inventor of ECMT-154 (as described in International Publication Number WO2022/234340 A1) and a shareholder of Manuka Bioscience. SH is also a contractor (R&D Strategist) at Manuka Bioscience. SH had input into protocol development, but is not involved in study conduct or data analysis. AS and GS declare funding from Manuka Bioscience to the MRINZ for the submitted work. There are no other conflicts of interest to declare.
